Overcoming Resistance to Drugs Targeting

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

54 citing papers in PubMed, 64 citations in OpenAlex.

1. Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors.Discover oncology · 2025
   Review
2. Palmitic acid and palmitoylation in cancer: Understanding, insights, and challenges.Innovation (Cambridge (Mass.)) · 2025
   Review
3. Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?Journal of experimental & clinical cancer research : CR · 2025
   Review
4. Differential Response and Resistance to KRAS-Targeted Therapy.Molecular carcinogenesis · 2025
   Review
5. [Role of antibiotic delivery system targeting bacterial biofilm based on ε-poly-Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2025
   Article
6. Advanced Technologies for Cancer Immunotherapy: Focus on Gastrointestinal Cancers.Anti-cancer agents in medicinal chemistry · 2025
   Review
7. A novel prognostic model for lung squamous cell carcinoma based on multi-omics analysis and machine learning.PloS one · 2025
   Article
8. Identification and Characterization of Novel Small-Molecule Enhancers of the CUL3ACS chemical biology · 2024
   Article
9. Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
   Article
10. Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands) · 2024
    Review
11. Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.Cancers · 2024
    Review
12. KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Current oncology (Toronto, Ont.) · 2024
    Review
13. Oncogenic alterations in advanced NSCLC: a molecular super-highway.Biomarker research · 2024
    Review
14. Resistance to KRAS inhibition in advanced non-small cell lung cancer.Frontiers in oncology · 2024
    Review
15. Insights into direct KRAS inhibition strategies for cancer treatment.Future medicinal chemistry · 2024
    Review
16. 143D, a novel selective KRASActa pharmacologica Sinica · 2023
    Article
17. RAS-targeted cancer therapy: Advances in drugging specific mutations.MedComm · 2023
    Review
18. Elimination of methicillin-resistant Staphylococcus aureus biofilms on titanium implants via photothermally-triggered nitric oxide and immunotherapy for enhanced osseointegration.Military Medical Research · 2023
    Article
19. Targeting PI3Kα overcomes resistance to KRasActa pharmacologica Sinica · 2023
    Article
20. Covalent inhibitor targets KRasGenes & diseases · 2023
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

Abstract

Indexed as